In terms of Human epidermal growth factor receptor 2 (HER2) status, 10 patients (12.7%) had HER2-positive GC, 59 (74.7%) had HER2-negative GC and the remaining 10 patients (12.7%) had unknown HER2 status. This evidence concerns the gene ERBB2 and gastric cancer.